Pathological and molecular evaluation of pancreatic neoplasms.

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to be an effective agent in the treatment of metastatic breast carcinoma. This multicenter randomized study compared paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks with mitomycin 12 mg/m2 given as an intravenous infusion ever...

journal_title：Seminars in oncology

authors： Dieras V,Marty M,Tubiana N,Corette L,Morvan F,Serin D,Mignot L,Chazard M,Garet F,Onetto N

更新日期：1995-08-01 00:00:00

abstract：:A dose-response relationship has long been suspected for progestin compounds in the treatment of breast cancer, but only recently have trials been implemented to investigate this issue. In 1985, we began a phase I-II study of high-dose megestrol acetate in dosages of 480 mg/d to 1,600 mg/d in heavily pretreated postme...

journal_title：Seminars in oncology

authors： Tchekmedyian NS,Tait N,Abrams J,Aisner J

更新日期：1988-04-01 00:00:00

abstract：:Recent insights into cell-mediated immunotherapy have led to a wave of new trials involving immunotherapy for prostate cancer. Vaccines have evolved from nonspecific immune stimulants like Bacillus Calmette-Guerin (BCG) to much more specific and potent strategies. Techniques currently being investigated include passiv...

journal_title：Seminars in oncology

authors： Hwang LC,Fein S,Levitsky H,Nelson WG

更新日期：1999-04-01 00:00:00

abstract：:Evidence is reviewed separating unusual variants of melanoma from the large group of superficial spreading and nodular (SSM/NOD) histogenetic types. These include (1) the relationship of moles to melanoma of the SSM/ NOD types not found in melanoma arising in lentigo maligna (LMM), desmoplastic neurotrophic melanoma (...

journal_title：Seminars in oncology

authors： Sagebiel RW

更新日期：1996-12-01 00:00:00

abstract：:Hypercalcemia of malignancy (HCM) is a potentially life-threatening complication of cancer resulting from increased bone resorption by osteoclasts. Clinical management of HCM primarily consists of intravenous rehydration therapy combined with pharmaceutical agents that decrease osteoclast activity. Several generations...

journal_title：Seminars in oncology

authors： Berenson JR

更新日期：2002-12-01 00:00:00

abstract：:One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activates multiple signaling cascades that promote carcinogenesis and immune evasion. Therefore, these molecules have been extensively targeted in cancer immunotherapy. Beyond EGFR signaling cascade inhibition, some of these agen...

journal_title：Seminars in oncology

authors： Mazorra Z,Chao L,Lavastida A,Sanchez B,Ramos M,Iznaga N,Crombet T

更新日期：2018-01-01 00:00:00

abstract：:Distant metastasis is the major cause for therapeutic failures in Clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease....

journal_title：Seminars in oncology

authors： Gilboa E

更新日期：1996-02-01 00:00:00

abstract：:Identification of tumor-, patient-, or treatment-related prognostic factors in renal carcinoma (RC) would allow the most appropriate application of current and future therapy to patients with this poorly responsive malignancy. Stage, including degree of lymph node and venous involvement, and grade remain the most powe...

journal_title：Seminars in oncology

authors： Rini BI,Vogelzang NJ

更新日期：2000-04-01 00:00:00

abstract：:Blast crisis terminates the life of the majority (approximately 80%) of patients with CML. The time of its onset appears to be a random phenomenon, varying from a probable coincidence occurrence with the onset of CML to more than a decade after onset of the chronic phase. In most patients the diagnosis is obvious as v...

journal_title：Seminars in oncology

authors： Boggs DR

更新日期：1976-09-01 00:00:00

abstract：:A phase I/II study was conducted to determine the response rate and the toxicity of escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin with granulocyte colony-stimulating factor support in patients with untreated advanced head and neck carcinoma. Twenty-eight patients wi...

journal_title：Seminars in oncology

authors： Hitt R,Paz-Ares L,Hidalgo M,Colomer R,Brandariz A,Peña M,Alvarez-Vicent J,Hornedo J,Cortés-Funes H

更新日期：1997-12-01 00:00:00

abstract：:Two children with biopsy-proven LCH underwent successful hepatic transplantation for end-stage liver disease. These patients were thought not to have active LCH disease at the time of transplantation, although one had developed a new osteolytic lesion a few months before the operation and the other had suspicious oste...

journal_title：Seminars in oncology

authors： Concepcion W,Esquivel CO,Terry A,Nakazato P,Garcia-Kennedy R,Houssin D,Cox KL

更新日期：1991-02-01 00:00:00

abstract：:The medical treatment of squamous cell cervical carcinoma is receiving increasing attention. Cisplatin and ifosfamide are known effective drugs. Paclitaxel has been tested with interesting results in cervical cancer. We evaluated the toxic effects and the antitumor activity of a multiagent regimen that included paclit...

journal_title：Seminars in oncology

authors： Zanetta G,Fei F,Mangioni C

更新日期：2000-02-01 00:00:00

abstract：:Recent studies have indicated that bone marrow angiogenesis is increased in multiple myeloma, suggesting that treatment with an antiangiogenic agent might be useful. Among the new antiangiogenic drugs in development, Neovastat (AE-941; Aeterna Laboratories, Quebec City, Canada) can be classified as a naturally occurri...

journal_title：Seminars in oncology

authors： Falardeau P,Champagne P,Poyet P,Hariton C,Dupont E

更新日期：2001-12-01 00:00:00

abstract：:Letrozole has proven efficacious in a variety of therapeutic scenarios, including that of extended adjuvant therapy following 5 years of tamoxifen treatment in postmenopausal women with estrogen-receptor-positive early breast cancer. The Breast International Group 1-98 trial (BIG 1-98) is the first to study the effica...

journal_title：Seminars in oncology

authors： Forbes JF

更新日期：2006-04-01 00:00:00

abstract：:Alterations in chromatin structure resulting from aberrant DNA methylation and perturbations of the histone code profoundly influence gene expression during pulmonary carcinogenesis. Recent studies indicate that DNA demethylating agents and histone deacetylase (HDAC) inhibitors synergistically induce gene expression a...

journal_title：Seminars in oncology

authors： Schrump DS,Nguyen DM

更新日期：2005-10-01 00:00:00

abstract：:The results of adjuvant chemotherapy in high-grade gliomas are disappointing. Carmustine (BCNU) wafers placed in the resection cavity provide a modest increase in median survival. However, the overall benefit of this approach is small, it offers no potential for cure, and the results are not statistically significant ...

journal_title：Seminars in oncology

authors： Grossman SA

更新日期：2003-12-01 00:00:00

abstract：:Lonidamine belongs to a new class of antineoplastics agents, since it does interfere with cell energy processes. When administered as single agent in metastatic breast cancer, it produces moderate therapeutic effects. The pattern of toxicity includes myalgias, asthenia, testicular pain, and gastrointestinal discomfort...

journal_title：Seminars in oncology

authors： Rosso R,Amoroso D,Gardin G,Miglietta L,Guido T,Pace M,Repetto L,Pronzato P

更新日期：1991-04-01 00:00:00

abstract：:The limited single-agent activity of cisplatin, its toxicity profile, and the inconvenience involved in hydrating patients has compelled researchers to investigate other treatments as possible alternative therapies in non-small cell lung cancer. More recently, interest has focused on the potential of nonplatinum combi...

journal_title：Seminars in oncology

authors： Georgoulias V,Scagliotti G,Miller V,Eckardt J,Douillard JY,Manegold C

更新日期：2001-02-01 00:00:00

abstract：:Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rate...

journal_title：Seminars in oncology

authors： Carney DN,Grogan L,Smit EF,Harford P,Berendsen HH,Postmus PE

更新日期：1990-02-01 00:00:00

abstract：:Cisplatin is recognized as an active chemotherapeutic agent in a broad variety of human tumors. The severe emetic effects of cisplatin, however, result in both acute and delayed emesis syndromes causing considerable morbidity. Over the last decade, the standard of therapy for control of cisplatin-induced emesis has be...

journal_title：Seminars in oncology

authors： Perez EA,Hesketh PJ,Gandara DR

更新日期：1991-02-01 00:00:00

abstract：:Evidence published during several decades has shown that there is a group of epithelial ovarian tumors having histological and biological features between those of clearly benign and frankly malignant tumors. In 1963, FIGO accepted an intermediate group of ovarian carcinomas of low malignant potential. In 1973, WHO ad...

journal_title：Seminars in oncology

authors： Tropé C,Kaern J

更新日期：1998-06-01 00:00:00

abstract：:Because results with conventional salvage therapy remain disappointing, the approach of using high-dose therapy and bone marrow transplantation has gained increasing support in recent years. Several trials have now been reported using various conditioning regimens and hematopoietic rescue sources. Although it is not c...

journal_title：Seminars in oncology

authors： Vose JM,Bierman PJ,Armitage JO

更新日期：1990-12-01 00:00:00

abstract：:A large meta-analysis showed that chemotherapy results in significant prolongation of survival for patients with non-small cell lung cancer (NSCLC). Pemetrexed is a new multitargeted antifolate chemotherapeutic agent that has shown activity in NSCLC and appears to be similar to the third-generation antitumor agents cu...

journal_title：Seminars in oncology

authors： Shepherd FA

更新日期：2002-12-01 00:00:00

abstract：:Pathologic complete response after neoadjuvant chemoradiation therapy is associated with increased survival in esophageal cancer. Early detection of response or nonresponse to neoadjuvant chemoradiation might allow individualization of treatment strategies and avoidance of unnecessary treatment. Positron emission tomo...

journal_title：Seminars in oncology

authors： Chao KS

更新日期：2006-12-01 00:00:00

abstract：:Over the past three decades conceptual approaches to breast cancer have led to improvements in locoregional therapy and early diagnosis. Systematic screening programs with mammography reduce disease-specific mortality by 25% to 30%, while many patients with early breast cancer receive optimal breast-conserving treatme...

journal_title：Seminars in oncology

authors： Hortobagyi GN,Hung MC,Buzdar AU

更新日期：1999-08-01 00:00:00

abstract：:Investigators representing all major melanoma research areas present an overview of the most important challenges for the field. Four major research areas are covered plus the training of new investigators. For each area we first describe the present status, its strengths and weaknesses, and then outline specific reco...

journal_title：Seminars in oncology

authors： Herlyn M,Halaban R,Ronai Z,Schuchter L,Berwick M,Pinkel D

更新日期：2007-12-01 00:00:00

abstract：:For any tumor to become cancerous, various genetic mutations and biologic alterations must occur in the cell that in combination render it a malignant neoplasm. Small cell lung cancer (SCLC) is a neoplasm associated with several molecular and cellular abnormalities. SCLC is associated with early and frequent metastasi...

journal_title：Seminars in oncology

authors： Sattler M,Salgia R

更新日期：2003-02-01 00:00:00

abstract：:Ten years of interferon (IFN) therapy have followed the approval of this agent by the US Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the many new biotherapeutics. Regardless of this long history, however, we have just touched the surface of understand...

journal_title：Seminars in oncology

authors： Pestka S

更新日期：1997-06-01 00:00:00

abstract：:The purpose of this study was to evaluate the combination of gemcitabine, paclitaxel, and carboplatin in patients with advanced non-small cell lung cancer. Previously untreated patients with stage IIIB or IV non-small cell lung cancer were enrolled into this trial. Sixty-nine patients from the phase II portion and eig...

journal_title：Seminars in oncology

authors： Burris HA 3rd,Hainsworth JD,Erland JB,Morrissey LH,Kalman LA,Hon JK,Scullin DC Jr,Smith SW,Greco FA

更新日期：2000-02-01 00:00:00

abstract：:The curative management of gastric adenocarcinoma depends on complete resection of the primary tumor. In patients with lymph node metastases in the resected specimen, the relapse and death rates from recurrent cancer are 70% to 80%. There is continued debate over whether more extensive lymph node dissection (D2) impro...

journal_title：Seminars in oncology

authors： Macdonald JS

更新日期：2003-08-01 00:00:00